000 | 01988 a2200541 4500 | ||
---|---|---|---|
005 | 20250517032615.0 | ||
264 | 0 | _c20151026 | |
008 | 201510s 0 0 eng d | ||
022 | _a1365-2141 | ||
024 | 7 |
_a10.1111/bjh.13493 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWitzig, Thomas E | |
245 | 0 | 0 |
_aA phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. _h[electronic resource] |
260 |
_bBritish journal of haematology _cSep 2015 |
||
300 |
_a679-86 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
650 | 0 | 4 | _aDisease-Free Survival |
650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunotherapy |
650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNeoplasm Staging |
650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
650 | 0 | 4 | _aRituximab |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 |
_aVincristine _xadministration & dosage |
700 | 1 | _aHong, Fangxin | |
700 | 1 | _aMicallef, Ivana N | |
700 | 1 | _aGascoyne, Randy D | |
700 | 1 | _aDogan, Ahmet | |
700 | 1 | _aWagner, Henry | |
700 | 1 | _aKahl, Brad S | |
700 | 1 | _aAdvani, Ranjana H | |
700 | 1 | _aHorning, Sandra J | |
773 | 0 |
_tBritish journal of haematology _gvol. 170 _gno. 5 _gp. 679-86 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjh.13493 _zAvailable from publisher's website |
999 |
_c24900723 _d24900723 |